Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
Howard P. Safran, Kathryn Winter, David H. Ilson, Dennis Wigle, Thomas DiPetrillo, Michael G. Haddock, Theodore S. Hong, Lawrence P. Leichman, Lakshmi Rajdev, Murray Resnick, Lisa A. Kachnic, Samantha Seaward, Harvey Mamon, Dayssy Alexandra Diaz Pardo, Carryn M. Anderson, Xinglei Shen, Anand K. Sharma, Alan W. Katz, Jonathan Salo, Kara L. LeonardJennifer Moughan, Christopher H. Crane
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial'. Together they form a unique fingerprint.